Inspection Record

Isomeric Pharmacy Solution, LLC — FDA 483 Findings

US FDAInspected 2017-08-04Published 2024-01-17 4 findingsAseptic processing and sterility assuranceStability and storageLaboratory and QC controls

Inspectors Zachery L Miller · Erika V ButlerThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.

2Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

3Stability and storage

There is no written testing program designed to assess the stability characteristics of drug products.

4Laboratory and QC controls

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Isomeric Pharmacy Solution, LLC company profile — full history US FDA documents, 2024 Go to Findings search